Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 686 clinical trials
Evaluation of a Oncology Day Care Unit Programme With Two Different Focuses

The aim of this study is to investigate the effects of a nature-centred integrative oncology day care unit programme ("outdoor concept") compared with an already established integrative oncology day care unit programme ("indoor concept").

cancer diagnosis
cancer
  • 0 views
  • 19 Feb, 2024
Tumor Electric Fields Treatment System for Glioblastoma

This early phase I trial will investigate the safety and feasibility of applying the Tumor Electric Fields Treatment System to subjects with recurrent glioblastoma.

recurrent glioblastoma
recurrent tumor
glioblastoma multiforme
  • 0 views
  • 19 Feb, 2024
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).

To determine the maximum tolerated dose(s) (MTD) or the Recommended Dose for Expansion (RDE) and dosing regimen for further development of BI 764532. The MTDs will be defined based on the frequency of patients experiencing dose limiting toxicities (DLTs) during the MTD evaluation period in studied regimens. The Recommended Dose …

  • 0 views
  • 19 Feb, 2024
Pantoprazole in Cisplatin Nephrotoxicity

Pantoprazole in Cisplatin Nephrotoxicity

neck cancer
cisplatin
nephrotoxicity
head and neck cancer
cancer
  • 0 views
  • 19 Feb, 2024
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel

Background People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers.

epinephrine
endometrial carcinosarcoma
neuroendocrine carcinoma
cholangiocarcinoma
spindle cell carcinoma of kidney
  • 0 views
  • 19 Feb, 2024
Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using RGD PET/CT Imaging

However, the incidence of human papillomavirus (HPV) related oropharyngeal carcinomas is increasing. It is known that HPV+ and HPV- tumors have a different reaction to (chemo)radiotherapy. The exact mechanisms underlying these differences is not yet known but might be caused by changes in vascularity.

immunohistochemistry
ct scan
ct perfusion
squamous cell carcinoma of the head and neck
oropharyngeal
  • 0 views
  • 19 Feb, 2024
Assess the Anti-tumor Activity and Safety of Glumetinib in Patient With Advanced c-MET-positive Non-Small Cell Lung Cancer

Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 15 patients Phase (globally): Approximately 90 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)

  • 0 views
  • 19 Feb, 2024
Optimising Radiation Therapy in Head and Neck Cancers Using Functional Image-Guided Radiotherapy and Novel Biomarkers

This is a non-randomised study to develop personalised treatment approaches in participants with Locally Advanced Head and Neck Cancer (HNC) of the oropharynx and base of skull by integrating the use of MR-guided Adaptive Radiotherapy (MRgRT) and functional image-guided radiotherapy (FIgRT).

metastasis
oropharyngeal
squamous cell carcinoma of head and neck
induction chemotherapy
chemo-radiotherapy
  • 0 views
  • 19 Feb, 2024
PSMA-specific CAR-T Cell Therapy

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of PSMA-specific CAR-T cell therapy in patients with PSMA positive tumor. Another goal of the study is to learn more about the function of the PSMA CAR-T cells and their persistency in the patients.

  • 0 views
  • 19 Feb, 2024
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

This is an open label Phase 1, First in Human trial of TST001, a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. It is being tested against advanced and/or metastatic solid tumors including gastric, gastroesophageal junction, pancreatic, colon and lung cancers.

monoclonal antibodies
cancer treatment
cancer
HER2
solid tumor
  • 0 views
  • 19 Feb, 2024